|By PR Newswire||
|September 4, 2014 12:36 PM EDT||
LONDON, Sept. 4, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
The 3D printing industry has come a long way over the last many years; the technology has the potential of revolutionising the way things occur currently. Many industries have already benefitted from multiple advancements in this field, resulting in improved and more efficient processes worldwide. A quick look at www.3dprintingchannel.com suggests that 3D printing has multi-faceted dimensions; the technology has recently been used in varied industries such as automotive, medical, business, industrial equipments, education, architecture, and consumer products. There is a widespread optimism that it is likely to gain prominence in the coming years and have a far reaching impact on our daily lives.
Within healthcare, 3D printed prosthetics and implants have already been in the market for some years. Layerwise from Belgium and Xilloc from Netherlands are the major companies dealing with 3D printed medical and dental implants. Xilloc was in the news recently for creating the first customized 3D-printed lower jaw for an 83-year old patient with a serious jaw infection. Another company, Oxford Performance Materials, from USA, received FDA approval for a 3D printed implant that replaced 75% of a man's skull.
Specifically, 3D bioprinting is gradually emerging as an area which is garnering attention from a lot of academicians. Some of these researchers have also recently opened start-up firms with the aim of commercialising the technology over the next decade or so.
SCOPE OF THE REPORT
The '3D Bioprinting, 2014 - 2030' report provides an extensive study of the emerging market of 3D bioprinting, specifically focusing on commercial bioprinters and those under development, their applications and the likely future evolution. It is widely anticipated that the 3D bioprinting market has tremendous potential: it requires hardware (bioprinters), software (CAD), biocompatible materials (bio-ink and bio-paper), each of which has the capability to grow into separate niche industries. The report covers various aspects such as technological progress, product pipeline, industry and academic research programs and regulatory concerns to assess new evolving opportunities.
One of the key objectives of this report is to understand the current and future state of the bioprinters and products derived thereof. This is done by analysing the following:
- Commercial 3D Bioprinters currently available in the market
- Innovations of academic groups across various research institutes across the globe
- Competing technologies with similar applications in the healthcare industry
- Size of target consumer segments
- The widening supply-demand gap, specifically for organ transplants.
The base year for the report is 2014. The report provides short-mid term and long term market forecasts for the period 2014 - 2024 and 2024 - 2030, respectively. We have discussed, in detail, key drivers behind the likely growth of 3D bioprinting market. The research, analysis and insights presented in this report include the sales potential of various 3D bioprinted products based on the current expected market launch timelines, their adoption rates and the estimated end-use price points. The figures mentioned in this report are in USD, unless otherwise specified.
1. As of today, the industry is primarily focused on research and development; apart from the limited number of industry initiatives, academic groups worldwide are involved in exemplary research in the field of 3D bioprinting.
2. A number of start-ups have recently sprung up to develop products based on bioprinting; some of these are spin outs from university research. Examples include TeViDo BioDevices (focused on printing breast tissue), Aspect Biosystems (focused on printing tissue models for toxicity testing) and SkinPrint (focused on developing human skin).
3. The market currently has 14 industry sponsored bioprinters, focused on a variety of commercial applications. The widening supply-demand gap for organ transplants is a huge unmet need; the eventual goal of researchers is to be able to produce bioprinted organs for organ transplants.
4. As the development progresses, the next generation of bioprinters are likely to offer additional features (e.g. multiple arms) and are likely to be relatively more affordable driving wider adoption.
5. We believe that the market will progress gradually over the coming decade; however, the focus is likely to shift from research to commercialisation by the second half of next decade. At this stage, applications such as drug testing and tissue engineering (skin and cartilage) are likely to be popular.
6. By 2030, we predict 3D bioprinting to be a multi-billion dollar industry; early success of bioprinted organ transplants is likely to provide additional boost in subsequent years.
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
1. Annual reports
2. Investor presentations
3. SEC filings
4. Industry databases
5. News releases from company websites
6. Government policy documents
7. Other analysts' opinion reports
While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the 3D bioprinting market is headed in the mid-long term.
Chapter 3 provides a general introduction to 3D bioprinting. We have discussed, in detail, the origins of 3D printing and recent developments which have shaped the industry so far. The chapter also elaborates on the 'bioprinting' process, current and future applications, and the challenges which have to be overcome before wider adoption of the technology.
Chapter 4 provides an overview of the 3D bioprinting market with respect to the available bioprinting technologies and companies active in the field. The analysis also extends to regional evolution and the key drivers which will determine the future growth.
Chapter 5 offers a comprehensive review of the major bioprinters which have been made available by leading companies in the market. We present profiles of eight technologies with information about their origin, printing process, applications, principal features, current status and expected future evolution.
Chapter 6 reviews, in detail, the major bioprinters offered by academic institutions dominant in the field. We present profiles of five leading technologies with information about their origin, printing process, applications, principal features, current status and likely future evolution.
Chapter 7 analyses the current and future state of the worldwide market of 3D bioprinting. The chapter includes our estimates of the value of the market for end-user applications till 2030. Given the current niche nature of the technology, we have done a multi-variate sensitivity analysis to present three different tracks of industry's evolution.
Chapter 8 provides our analysis of the strengths, weaknesses, opportunities and threats in the 3D bioprinting market, capturing the key elements likely to influence future growth.
Chapter 9 provides case studies on Organovo and regenHU, two companies active in the 3D bioprinting arena. The case studies include detailed analysis of financial performance (where available), marketed / pipeline bioprinting products, recent developments, and future focus areas.
Chapter 10 is a collection of six transcripts based on our discussion with some of the leading players in the industry. The companies / academic institutes interviewed include n3D Biosciences, regenHU, Sciperio / nScrypt, MicroFab Technologies, Digilab and TeVido BioDevices.
Chapter 11 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapters 12 and 13 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3.1. Chapter Overview
3.2. 3D Printing Technology
3.2.1. What is 3D Printing?
3.2.2. Historical Evolution
3.3. 3D Bioprinting Process And Components
3.4. Entry of 3D Printing into Medical Arena
3.4.1. Key Players
3.4.2. 3D Bioprinting Applications
22.214.171.124. Toxicity Screening / Drug Testing
126.96.36.199. Tissue Engineering
188.8.131.52. Organ Replacement via Organ Printing
184.108.40.206. High Initial Cost
220.127.116.11. Regulatory Issues
18.104.22.168. Functional Aspects Not Yet Fully Tested
22.214.171.124. Limited Capability for Complicated Tissues and Organs
126.96.36.199. Hurts Moral and Religious Beliefs
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Limited Professional Bioprinters in Market
4.3. Prices are Largely Prohibitive
4.4. The US is Leading the Efforts; Developing Countries Have Begun to Contribute
4.5. Start-ups Emerging as Key Players
4.6. Bioprinting: Finding its Root in University Research
4.7. Development of Multi-Arm Bioprinters: The Next Generation of Bioprinters
5. PROFILES: COMMERCIAL BIOPRTINERS AND PRODUCTS
5.1. Chapter Overview
5.2. Novogen MMX - Organovo
5.2.1. Overview and Origin
5.2.2. Development of NovoGen MMX
5.2.4. Awards and Accomplishments
5.2.5. The Bioprinting Process
5.2.7. Key Features
188.8.131.52. Microtissues for Drug Discovery and Research
184.108.40.206. Longer Term, Organ Printing for Transplantation
220.127.116.11. Regenerative Medicine
5.2.9. Partnerships and Agreements
18.104.22.168. United Therapeutics
22.214.171.124. Methuselah Foundation
5.3. 3D-Bioplotter - EnvisionTEC
5.3.1. Overview and Origin
5.3.2. The Bioprinting Process
126.96.36.199. Provides 'smart' scaffolds for tissue engineering
188.8.131.52. Cell and Tissue Printing
184.108.40.206. 3D-Anatomical Models for Study
5.3.4. Key Features
5.3.5. Academic Institutions using 3D Bioplotter
5.4. BioFactory - regenHU
5.4.1. Overview and Origin
5.4.3. Research Collaborations
220.127.116.11. ETH, Zurich
5.5. BioAssembly Tool - Sciperio / nScrypt
5.5.1. Overview and Origin
5.5.2. The Bioprinting Process
5.5.3. Key Features
18.104.22.168. Cardiovascular Innovation Institute
5.5.5. Awards / Accomplishments
22.214.171.124. Bioficial Heart
126.96.36.199. Other Tissues
5.6. Microfluidic-based Bioprinting Platform - Aspect Biosystems
5.6.1. Overview and Origin
5.6.2. The Bioprinting Process
5.6.3. Key Features
5.6.4. Building Tissue Constructs For Drug Discovery
188.8.131.52. MEMSCAP Design Award 2013
184.108.40.206. Federal Support Through IRAP
5.7. Modified Ink-jet Bioprinter - TeVido BioDevices
5.7.1. Overview and Origin
5.7.3. The Bioprinting Process
5.7.4. Key Features
220.127.116.11. Breast Reconstruction
18.104.22.168. Drug Testing
22.214.171.124. Other Reconstructive Tissue Products
126.96.36.199. Treatment for Chronic Wounds
188.8.131.52. Breast Augmentation
5.8. Other Initiatives
5.8.2. 3DDiscovery - regenHU
184.108.40.206. Key Features
220.127.116.11. Research Collaborations
6. PRODUCT PROFILES: ACADEMIC INSTITUTES
6.1. Chapter Overview
6.2. BioPen - University of Wollongong / St. Vincent Hospital
6.2.1. Overview and Origin
6.2.2. The Bioprinting Process
6.2.3. Advantages of BioPen
6.3. Modified Ink-jet Bioprinter for Skin Cells - Wake Forest Institute for Regenerative Medicine / Armed Forces Institute For Regenerative Medicine
6.3.2. The Bioprinting Process
6.3.3. Key Features
6.3.4. Bioprinting Human Skin
6.3.5. Awards / Accomplishments
6.4. Modified Ink-jet Printer for Tissues and Organs - Wake Forest Institute for Regenerative Medicine
6.4.2. The Bioprinting Process
18.104.22.168. Tissue Patches
22.214.171.124. Potential to Print Organs
126.96.36.199. Organs on a Chip
6.5. Regenovo - Hangzhou Dianzi University, China
6.5.2. The Bioprinting Process
6.5.3. Key Features
6.6. Valve Based Technology - Heriot-Watt University / Roslin Cellab
6.6.1. Overview and Origin
6.6.2. The Bioprinting Process
6.6.3. Key Features
188.8.131.52. Drug Testing for Pharmaceutical Research
184.108.40.206. Tissue Regeneration
220.127.116.11. Custom-built Replacement Organs
6.6.5. Awards / Accomplishments
18.104.22.168. Reinnervate Ltd.
7. MARKET FORECAST
7.1. Chapter Overview
7.2. Forecast Methodology
7.3. The 3D Bioprinting Market, 2014 - 2030
7.3.2. Market Forecast: Drug Testing (Base Scenario)
7.3.3. Market Forecast: 3D Bioprinted Skin (Base Scenario)
7.3.4. Market Forecast: 3D Printed Cartilage Replacement (Base Scenario)
7.3.5. Market Forecast: 3D Printed Organ Transplants (Base Scenario)
7.3.6. Overall Market Forecast (Base Scenario)
8. SWOT ANALYSIS
8.1. Chapter Overview
8.2.1. Faster Drug Discovery
8.2.2. A Quality Alternative to Animal Testing
8.3.1. High Initial Investment
8.3.2. Integration of Vascular Network
8.4.1. Low Entry Barriers
8.4.2. Growing Wait List for Organ Transplants – A Huge Unmet Need
8.5.1. Regulatory Barrier
8.5.2. Commercial 3D Cell Culture Systems
9. CASE STUDIES
9.1. Organovo Holdings, Inc.
10. INTERVIEW TRANSCRIPTS
10.1. Interview 1: n3D Biosciences (Glauco R. Souza, President and CSO & Hubert Tseng, Senior Research Scientist)
10.2. Interview 2: regenHU (Marc Thurner, CEO)
10.3. Interview 3: Sciperio / nScrypt (Kenneth Church, President and CEO & Xudong Chen, Vice President)
10.4. Interview 4: MicroFab Technologies (Anonymous)
10.5. Interview 5: Digilab (Dr. Igor Zlatkin, Application Scientist & Chirantan Kanani, Technology and Product Development)
10.6. Interview 6: TeVido BioDevices (Laura Bosworth, CEO and Co-Founder)
11.1. 3D Bioprinting has Emerged Well Since Inception
11.2. Commercial Bioprinters Are Limited; Research Labs and Spin-outs from Academia Continue to Progress
11.3. Organ Supply - Demand Gap: A Major Growth Driver
11.4. Overall a Multi-billion Dollar Opportunity by 2030
11.5. Challenges Exist Before Bioprinting Becomes Mainstream
12. APPENDIX 1: LIST OF COMPANIES AND ORGANISATIONS
13. APPENDIX 2: TABLES
LIST OF FIGURES
Figure 3.1 The 'Bioprinting' Process
Figure 4.1 Industry Sponsored Bioprinters: Regional Distribution
Figure 4.2 Industry Sponsored Bioprinters: Distribution by Status
Figure 4.3 University Sponsored Bioprinters: Regional Distribution
Figure 5.1 Bioplotter: Printing Process
Figure 7.1 Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.2 Drug Testing Market, Long Term, Base Scenario (USD MM)
Figure 7.3 3D Bioprinted Skin Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.4 3D Bioprinted Skin Market, Long Term, Base Scenario (USD MM)
Figure 7.5 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.6 3D Bioprinted Cartilage Replacement Market, Long Term, Base Scenario (USD MM)
Figure 7.7 3D Bioprinted Organ Transplants, Long Term, Base Scenario (USD MM)
Figure 7.8 Overall 3D Bioprinted Products Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.9 Overall 3D Bioprinted Products Market, Long Term, Base Scenario (USD MM)
Figure 10.1 Process of Magnetic Bioprinting
Figure 10.2 3D Cell Bioprinting: Magnetically Beyond Rings and Dots
Figure 10.3 n3D vs. Organovo 3D Bioprinting
Figure 11.1 3D Bioprinting Market, 2018, 2024, 2030 (USD MM)
Figure 11.2 3D Bioprinting: The Driving Forces
LIST OF TABLES
Table 3.1 RepRap Project: 3D Printing Machines
Table 3.2 Inputs for 3D Bioprinting
Table 4.1 List of Bioprinters: Industry Sponsored
Table 4.2 Companies Developing Bioprinted Products for Commercial Purposes
Table 4.3 Universities Working in the Area of Bioprinting
Table 5.1 NovoGen MMX: Patent Portfolio
Table 5.2 Materials Used for Scaffolds
Table 5.3 SmartPump - Models and Features
Table 7.1: 3D Bioprinted Applications: Launch Timeline
Table 7.2 3D Bioprinted Skin: Competitive Landscape
Table 8.1 SWOT Analysis
Table 8.2 3D Cell Culture Systems
Table 9.1 3D Liver Assays - Launch Timeline
Table 9.2 Organovo's Plans for Revenue Generation from 3D Bioprinted Liver
Table 9.3 Organovo Revenues – 2011, 2012, and Q1 2013
Table 9.4 regenHU: 3D Bioprinting Product Portfolio
Table 13.1 Industry Sponsored Bioprinters: Regional Distribution
Table 13.2 Industry Sponsored Bioprinters: Distribution by Status
Table 13.3 University Sponsored Bioprinters: Regional Distribution
Table 13.4 Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.5 Drug Testing Market, Long Term, Base Scenario (USD MM)
Table 13.6 Drug Testing Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.7 Drug Testing Market, Long Term, Conservative Scenario (USD MM)
Table 13.8 Drug Testing Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.9 Drug Testing Market, Long Term, Optimistic Scenario (USD MM)
Table 13.10 3D Bioprinted Skin Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.11 3D Bioprinted Skin Market, Long Term, Base Scenario (USD MM)
Table 13.12 3D Bioprinted Skin Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.13 3D Bioprinted Skin Market, Long Term, Conservative Scenario (USD MM)
Table 13.14 3D Bioprinted Skin Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.15 3D Bioprinted Skin Market, Long Term, Optimistic Scenario (USD MM)
Table 13.16 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.17 3D Bioprinted Cartilage Replacement Market, Long Term, Base Scenario (USD MM)
Table 13.18 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.19 3D Bioprinted Cartilage Replacement Market, Long Term, Conservative Scenario (USD MM)
Table 13.20 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.21 3D Bioprinted Cartilage Replacement Market, Long Term, Optimistic Scenario (USD MM)
Table 13.22 3D Bioprinted Organ Transplants, Long Term, Base Scenario (USD MM)
Table 13.23 3D Bioprinted Organ Transplants, Long Term, Conservative Scenario (USD MM)
Table 13.24 3D Bioprinted Organ Transplants, Long Term, Optimistic Scenario (USD MM)
Table 13.25 3D Bioprinted Products Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.26 3D Bioprinted Products Market, Long Term, Base Scenario (USD MM)
Table 13.27 3D Bioprinted Products Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.28 3D Bioprinted Products Market, Long Term, Conservative Scenario (USD MM)
Table 13.29 3D Bioprinted Products Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.30 3D Bioprinted Products Market, Long Term, Optimistic Scenario (USD MM)
The following companies have been mentioned in the report.
1. 3D Biotek
2. 3D Systems
3. Advanced Biomatrix
5. Aspect Biosystems
8. Avita Medical
9. BD Biosciences
10. Bespoke Innovations
11. Bio3D Technologies
13. CMC Microsystems
15. CP Automation
16. Cuspis LLC
17. Cyfuse Biomedical
23. Hangzhou Dianzi University, China
24. Helisys Inc.
25. Heriot-Watt University
28. InSphero AG
32. Kor Ecologic
34. MakerBot Industries
36. Methuselah Foundation
37. MicroFab Technologies
38. Modern Meadows
39. n3D Biosciences
40. Nano3D Biosciences
41. National Institute of Health
44. Objective 3D
45. Objet Geometries Ltd
46. Organovo Holdings, Inc.
47. Oregon Health & Science University
48. Oxford Performance Materials
51. Rainbow Biosciences
55. Roland DG Corporation
56. Roslin Cellab
58. Sciperio / nScrypt
60. Seattle Genetics
65. TeVido BioDevices
66. The Technology Partnership
67. Unique Technology
68. United Therapeutics
70. Vivos Dental
71. Wake Forest Institute for Regenerative Medicine
75. Z Corporation
77. Zurich University of Applied Sciences
The Internet of Things promises to transform businesses (and lives), but navigating the business and technical path to success can be difficult to understand. In his session at @ThingsExpo, Sean Lorenz, Technical Product Manager for Xively at LogMeIn, demonstrated how to approach creating broadly successful connected customer solutions using real world business transformation studies including New England BioLabs and more.
Dec. 26, 2014 08:15 AM EST Reads: 2,003
"ElasticBox is an enterprise company that makes it very easy for developers and IT ops to collaborate to develop, build and deploy applications on any cloud - private, public or hybrid," stated Monish Sharma, VP of Customer Success at ElasticBox, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 26, 2014 08:15 AM EST Reads: 1,765
SYS-CON Events announced today that Gridstore™, the leader in hyper-converged infrastructure purpose-built to optimize Microsoft workloads, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Gridstore™ is the leader in hyper-converged infrastructure purpose-built for Microsoft workloads and designed to accelerate applications in virtualized environments. Gridstore’s hyper-converged infrastructure is the ...
Dec. 26, 2014 08:00 AM EST Reads: 1,794
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at @ThingsExpo, Robin Raymond, Chief Architect...
Dec. 26, 2014 07:30 AM EST Reads: 2,113
"Matrix is an ambitious open standard and implementation that's set up to break down the fragmentation problems that exist in IP messaging and VoIP communication," explained John Woolf, Technical Evangelist at Matrix, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 26, 2014 06:00 AM EST Reads: 1,940
An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
Dec. 26, 2014 06:00 AM EST Reads: 2,318
We are reaching the end of the beginning with WebRTC, and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will w...
Dec. 26, 2014 05:00 AM EST Reads: 1,868
DevOps is all about agility. However, you don't want to be on a high-speed bus to nowhere. The right DevOps approach controls velocity with a tight feedback loop that not only consists of operational data but also incorporates business context. With a business context in the decision making, the right business priorities are incorporated, which results in a higher value creation. In his session at DevOps Summit, Todd Rader, Solutions Architect at AppDynamics, discussed key monitoring techniques...
Dec. 26, 2014 05:00 AM EST Reads: 1,777
The 3rd International @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to th...
Dec. 26, 2014 04:15 AM EST Reads: 2,673
SYS-CON Media announced that Centrify, a provider of unified identity management across cloud, mobile and data center environments that delivers single sign-on (SSO) for users and a simplified identity infrastructure for IT, has launched an ad campaign on Cloud Computing Journal. The ads focus on security: how an organization can successfully control privilege for all of the organization’s identities to mitigate identity-related risk without slowing down the business, and how Centrify provides ...
Dec. 26, 2014 04:00 AM EST Reads: 1,738
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, discussed how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will need to convince a skeptical public to participate. Get ready to show them the money!
Dec. 26, 2014 04:00 AM EST Reads: 1,977
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
Dec. 26, 2014 02:45 AM EST Reads: 2,121
The term culture has had a polarizing effect among DevOps supporters. Some propose that culture change is critical for success with DevOps, but are remiss to define culture. Some talk about a DevOps culture but then reference activities that could lead to culture change and there are those that talk about culture change as a set of behaviors that need to be adopted by those in IT. There is no question that businesses successful in adopting a DevOps mindset have seen departmental culture change, ...
Dec. 26, 2014 01:45 AM EST Reads: 1,611
In her General Session at 15th Cloud Expo, Anne Plese, Senior Consultant, Cloud Product Marketing, at Verizon Enterprise, focused on finding the right mix of renting vs. buying Oracle capacity to scale to meet business demands, and offer validated Oracle database TCO models for Oracle development and testing environments. Anne Plese is a marketing and technology enthusiast/realist with over 19+ years in high tech. At Verizon Enterprise, she focuses on driving growth for the Verizon Cloud platfo...
Dec. 26, 2014 01:00 AM EST Reads: 2,445
"There is a natural synchronization between the business models, the IoT is there to support ,” explained Brendan O'Brien, Co-founder and Chief Architect of Aria Systems, in this SYS-CON.tv interview at the 15th International Cloud Expo®, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 26, 2014 12:00 AM EST Reads: 2,833